MedPath

Tagged News

Certara Appoints AI Pioneer Dr. Chris Bouton as CTO to Advance Next-Generation Drug Development Platform

AI
  • Certara has appointed Dr. Christopher Bouton, founder of Vyasa Analytics, as Chief Technology Officer to lead development of an AI-powered model-informed drug development platform.
  • Dr. Bouton will spearhead technology strategy for integrating generative AI and biosimulation technology to accelerate drug discovery and development timelines.
  • The appointment strengthens Certara's position in the competitive biosimulation market, building on Bouton's track record of developing AI solutions including CoAuthor™ for regulatory writing.
  • Certara's next-generation platform aims to increase efficiency in discovering novel therapeutics by combining scientific expertise with advanced AI approaches.

ChatGPT Reduces Clinical Trial Screening Time from 40 Minutes to Under 3 Minutes, But Human Oversight Still Required

AIOncology
  • ChatGPT-4 demonstrated superior performance over ChatGPT-3.5 in screening patients for clinical trials, achieving 84% accuracy with better sensitivity and specificity balance.
  • Screening times were dramatically reduced from over 40 minutes per patient to 1.4-3.0 minutes with GPT-3.5 and 7.9-12.4 minutes with GPT-4, though costs ranged from $0.02-$0.27 per patient.
  • Both AI models showed high specificity but low sensitivity in identifying eligible patients, with GPT-4 having only 16% median sensitivity despite 100% specificity.
  • Researchers concluded that large language models should complement rather than replace manual chart reviews due to difficulties in identifying patients who meet all eligibility criteria.

Protopia AI Secures $1.25M Air Force Contract to Advance Privacy-Preserving AI Technology for Secure Code Development

AI
  • Protopia AI received a $1.25 million Direct-to-Phase II SBIR contract from the U.S. Air Force to demonstrate its Stained Glass Transform technology for secure AI-powered software development.
  • The technology enables Air Force teams to use coding large language models without exposing proprietary codebases in plain text, addressing critical security concerns in AI adoption.
  • This partnership with the Air Force Sustainment Center Software Directorate represents a significant milestone for privacy-preserving AI applications in mission-critical environments.
  • The contract highlights the growing need for dual-use technologies that enable secure generative AI adoption across both military and commercial applications.

Ultromics Secures $55M Series C to Scale AI-Powered Heart Failure Diagnostics Across US Hospitals

AI
  • Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.
  • The AI-powered diagnostic tool improved HFpEF detection by 73.6% compared to traditional methods and has analyzed over 430,000 echocardiograms to date.
  • With Medicare reimbursement secured and partnerships with major health systems including UChicago Medicine and Mayo Clinic, the platform addresses a critical diagnostic gap where up to 64% of heart failure cases go undetected.
  • Heart failure drives over $30 billion in annual US healthcare costs, projected to exceed $70 billion by 2030, highlighting the urgent need for improved diagnostic capabilities.

Fresenius Medical Care Partners with Azenta to Advance Precision Kidney Disease Care Through Genomic Analysis

Precision MedicineAI
  • Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences have formed a strategic collaboration to advance genomic analysis of Frenova's My Reason® genomics research program.
  • The My Reason® program has registered over 35,000 participants with biospecimens, aiming to reach 50,000 participants over the next two years to build the world's most comprehensive kidney disease database.
  • The collaboration will leverage whole genome sequencing and AI/machine learning models to identify novel disease subtypes, protective genetic variants, and therapeutic targets for cardio-kidney-metabolic diseases.
  • GENEWIZ will provide DNA sequencing technologies and long-term sample storage through Azenta's global biorepository network to extract insights from the genomic and clinical data registry.

Inka Health Partners with OneMedNet to Develop AI-Powered External Control Arms for Cancer Drug Development

AIReal World EvidenceOncology
  • Inka Health has been selected by OneMedNet to lead a data analytics initiative using real-world data to develop external control arms as a faster, more cost-effective alternative to traditional clinical trials.
  • The project will deploy Inka Health's proprietary SynoGraph platform to build and validate an external control arm for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer.
  • This collaboration aims to accelerate market entry for new cancer therapies by offering a more efficient path to generate evidence needed for regulatory and reimbursement approvals.
  • The initiative positions both companies in the rapidly expanding Real-World Evidence market, projected to exceed $4.6 billion globally by 2030.

Topcon Acquires AI-Powered Diabetic Retinopathy Screening Company IRIS to Expand Connected Care Platform

AI
  • Topcon Healthcare acquired Intelligent Retinal Imaging Systems (IRIS), a cloud-based retinal screening technology company, to integrate AI-powered diabetic retinopathy screening into its Healthcare from the Eye initiative.
  • IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy across 650+ healthcare organizations since its founding in 2012.
  • The acquisition will strengthen Topcon's Harmony platform by adding IRIS's referral and communication capabilities to improve care coordination between primary care and eye care providers.
  • The integration aims to enable early identification of patients at risk of ocular disease during primary care visits and facilitate timely referrals to eye care specialists.

AI-Driven Drug Repurposing Identifies Four FDA-Approved Medications with Lipid-Lowering Effects

AI
  • Researchers used machine learning to analyze 3,430 FDA-approved drugs and identified 29 candidates with potential lipid-lowering effects, addressing treatment gaps for patients who cannot tolerate statins.
  • Clinical validation using 25 years of hospital records confirmed significant lipid reductions for four drugs: Argatroban reduced LDL cholesterol by 33%, while Levoxyl, oseltamivir, and thiamine showed moderate but significant effects.
  • Mouse studies and molecular docking analysis revealed distinct mechanisms of action for the identified drugs, with Argatroban showing particularly strong binding to coagulation factor X and other candidates targeting various lipid metabolism pathways.

MAGENTIQ EYE Secures Series A Funding to Advance AI-Powered Colonoscopy Technology

AIFDA Approval
  • MAGENTIQ EYE completed its Series A funding round led by aMoon to accelerate commercialization of its FDA- and CE-approved AI colonoscopy software MAGENTIQ-COLO in the USA and Europe.
  • The company's AI-powered software significantly improves adenoma detection rates during colonoscopies and offers real-time polyp analysis with size and type estimation capabilities.
  • Funding will support ongoing clinical trials for diagnostic tools targeting ulcerative colitis, Barrett's esophagus dysplasia, and gastric intestinal metaplasia while expanding global market access.
  • The investment reflects growing commercial traction with dozens of daily procedures and a robust pipeline of trial and purchase requests across international markets.

Cardiosense Receives FDA Clearance for CardioTag, First Wearable to Monitor Heart Rhythm and Mechanical Function

AI
  • Cardiosense announced FDA 510(k) clearance for CardioTag, the first wearable device to simultaneously collect ECG, PPG, and seismocardiogram signals for comprehensive cardiac monitoring.
  • The device enables clinicians to assess not only heart rhythm but also mechanical and hemodynamic function, providing unprecedented visibility into cardiac performance across care settings.
  • A recent multicenter study showed Cardiosense's AI algorithm for pulmonary capillary wedge pressure estimation achieved accuracy comparable to implantable hemodynamic sensors in heart failure patients.
  • The clearance represents a significant advancement in noninvasive cardiac monitoring, moving beyond traditional ECG-focused approaches to include cardiac mechanics and blood flow assessment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.